Thus, this systematic review and meta-analysis aimed to evaluate the efficacy of EGFR-TKI retreatment following a TKI-free interval in NSCLC patients who were initially treated with EGFR-TKIs in the first-line setting on a clinical trial and in the real-world setting. This evidence concerns the gene EGFR and non-small cell lung carcinoma.